The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status

Akman, Tülay; Öztop, İlhan; Baskın, Yasemin; Ünek, İlkay Tuğba; Demir, Neclå; Ellıdokuz, Hülya; Yılmaz, Ahmet

doi:10.4103/0973-1482.148684

Cited by 9 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A retrospective analysis of 273 patients with mCRC demonstrated a significant correlation between KRAS status and clinical outcomes. Some data have shown that patients with a mutated KRAS Codon 13 have more aggressive disease than those with mutations in Codon 12, but much controversy still exists ( 60 , 61 ). Recent progress has been made in targeting KRAS (G12C) with a specific covalent inhibitor, such as ARS-853, AMG510, MRTX849, or ARS3248 ( 62 ).…”

Section: Discussionmentioning

confidence: 99%

Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer

et al. 2022

View full text Add to dashboard Cite

In the United States, CRC is the third most common type of cancer and the second leading cause of cancer-related death. Although the incidence of CRC among the Hispanic population has been declining, recently, a dramatic increase in CRC incidents among HL younger than 50 years of age has been reported. The incidence of early-onset CRC is more significant in HL population (45%) than in non-Hispanic Whites (27%) and African-Americans (15%). The reason for these racial disparities and the biology of CRC in the HL are not well understood. We performed this study to understand the biology of the disease in HL patients. We analyzed formalin-fixed paraffin-embedded tumor tissue samples from 52 HL patients with mCRC. We compared the results with individual patient clinical histories and outcomes. We identified commonly altered genes in HL patients (APC, TP53, KRAS, GNAS, and NOTCH). Importantly, mutation frequencies in the APC gene were significantly higher among HL patients. The combination of mutations in the APC, NOTCH, and KRAS genes in the same tumors was associated with a higher risk of progression after first-line of chemotherapy and overall survival. Our data support the notion that the molecular drivers of CRC might be different in HL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One mechanism highlighted in CRC cells underlines a possible role of the small GTPase KRAS in miRNA sorting. KRAS mutations occur in more than a third of sporadic colorectal cancers, and it has been associated with several other cancers, in particular, regarding tumor aggressiveness [85–87]. Exosomes secreted by KRAS mutant CRC cells can induce growth and migration of wild type (WT) cells [88, 89].…”

Section: Exosomal Mirnas In Crcmentioning

confidence: 99%

Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer

Vautrot

Chanteloup

Elmallah

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the major causes of cancer-related deaths worldwide. Tumor microenvironment (TME) contains many cell types including stromal cells, immune cells, and endothelial cells. The TME modulation explains the heterogeneity of response to therapy observed in patients. In this context, exosomes are emerging as major contributors in cancer biology. Indeed, exosomes are implicated in tumor proliferation, angiogenesis, invasion, and premetastatic niche formation. They contain bioactive molecules such as proteins, lipids, and RNAs. More recently, many studies on exosomes have focused on miRNAs, small noncoding RNA molecules able to influence protein expression. In this review, we describe miRNAs transported by exosomes in the context of CRC and discuss their influence on TME and their potential as circulating biomarkers. This overview underlines emerging roles for exosomal miRNAs in cancer research for the near future.

show abstract

“… 53 - 56 KRAS mutation correlates with various clinical and clinicopathological features in CRC populations, including sex, 57 - 61 age at diagnosis (>50 years), 58 tumor location, 56 , 57 , 61 tumor differentiation, 56 , 61 - 63 and Tumor, Lymph-node, Metastasis (TNM) stage. 60 However, some studies did not find significant associations 64 , 65 in this context. In our study, men constituted most (58.6%) of the cohort, with tumor sites predominantly in the left colon (51.9%).…”

Section: Discussionmentioning

confidence: 72%

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Benmokhtar,

Laraqui,

Hilali

et al. 2024

Clin Med Insights Oncol

View full text Add to dashboard Cite

Background: This review article aims to investigate the prevalence and spectrum of rat sarcoma (RAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutations, and their connection with geographical location, clinicopathological features, and other relevant factors in colorectal cancer (CRC) patients in the Middle East. Methods: A systematic literature review, employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework, was conducted to investigate the association between the frequency of relevant mutations and the descriptive clinicopathological characteristics of CRC patients. Multiple electronic databases, including PubMed, Science Direct, Web of Science, Scopus, and Google Scholar, were searched to analyze the relevant literature. Results: A total of 19 eligible studies comprising 2960 patients with CRC were included in this review. A comprehensive analysis of the collected literature data as well as descriptive and methodological insights is provided. Men were predominant in reviewed studies for the region, accounting for 58.6%. Overall, RAS mutation prevalence was 38.1%. Kirsten RAS Viral Oncogene Homolog (KRAS) mutations were the most common, accounting for 37.1% of cases and distributed among different exons, with the G12D mutation being the most frequent in exon 2 (23.2%) followed by G12V (13.7%), G13D (10.1%), G12C (5.1%), G12A (5.04%), and G12S (3.6%). Neuroblastoma RAS Viral Oncogene Homolog (NRAS) mutations were identified in 3.3% of tumor samples, with the most common mutation site located in exons 2, 3, and 4, and codon 61 being the most common location for the region. The total mutation frequency in the BRAF gene was 2.6%, with the V600E mutation being the most common. Conclusion: The distribution patterns of RAS and BRAF mutations among CRC patients exhibit notable variations across diverse ethnic groups. Our study sheds light on this phenomenon by demonstrating a higher prevalence of KRAS mutations in CRC patients from the Middle East, as compared with those from other regions. The identification of these mutations and geographical differences is important for personalized treatment planning and could potentially aid in the development of novel targeted therapies. The distinct distribution patterns of RAS and BRAF mutations among CRC patients across different ethnic groups, as well as the regional variability in mutation prevalence, highlight the need for further research in this area.

show abstract

The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status

Abstract: As a result, the effect of KRAS mutation status on clinicopathological features, survival time and prognosis is unclear.

Cited by 9 publications

References 2 publications

Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer

Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer

Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer

RAS/RAF/MAPK Pathway Mutations as Predictive Biomarkers in Middle Eastern Colorectal Cancer: A Systematic Review

Contact Info

Product

Resources

About